|
Sep 5
|
Novo Nordisk’s Ozempic Shortage Is Worsening. That’s Good for Eli Lilly Stock.
|
|
Sep 5
|
Eli Lilly Makes Strides on Weekly Insulin Shot as Novo Nordisk Stumbles
|
|
Sep 5
|
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
|
|
Sep 5
|
Lilly builds case for weekly insulin shot
|
|
Sep 4
|
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
|
|
Sep 4
|
High-dose Spinraza meets study goal; Top Dyne executives exit
|
|
Sep 3
|
Viking Surges 342% in the Past Year: How Should You Play the Stock?
|
|
Sep 3
|
UAE MoHAP and Novo Nordisk partner for obesity management
|
|
Aug 31
|
3 No-Brainer Stocks to Buy in September
|
|
Aug 31
|
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
|
|
Aug 30
|
Catalent delays filing of annual report
|
|
Aug 30
|
Eli Lilly ramps up its fight against imitation weight-loss drugs
|
|
Aug 30
|
The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
|
|
Aug 30
|
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
|
|
Aug 30
|
Wegovy reduces Covid-19 deaths and illness, study finds
|
|
Aug 30
|
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
|
|
Aug 29
|
Catalent beats revenue estimates ahead of deal close with Novo Holdings
|
|
Aug 29
|
Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day
|
|
Aug 28
|
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
|
|
Aug 28
|
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
|